Design and Synthesis of Thiadiazoles and Thiazoles Targeting the Bcr-Abl T315I Mutant: from Docking False Positives to ATP-Noncompetitive Inhibitors
作者:Marco Radi、Emmanuele Crespan、Federico Falchi、Vincenzo Bernardo、Samantha Zanoli、Fabrizio Manetti、Silvia Schenone、Giovanni Maga、Maurizio Botta
DOI:10.1002/cmdc.201000066
日期:——
previously identified dual Src/Abl hits, a new series of 1,3,4‐thiadiazoles and 1,3‐thiazoles were designed and synthesized, paying particular attention to the reduction of their lipophilicity and to the improvement of the affinity towards the drug‐resistant T315I mutant. Compound 5 was identified as a promising allosteric inhibitor of the T315I mutant.
克服耐药性:为了优化我们先前确定的双重Src / Abl命中率,设计并合成了一系列新的1,3,4-噻二唑和1,3-噻唑,特别注意降低它们的亲脂性和对耐药T315I突变体亲和力的提高。化合物5被确定为T315I突变体的有希望的变构抑制剂。